• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CardiAQ Valve touts TMVI procedure

CardiAQ Valve touts TMVI procedure

June 24, 2015 By Fink Densford

CardiAQ Valve touts TMVI procedureCardiAQ Valve Technologies said yesterday that it successfully implanted its 2nd generation transcatheter bioprosthetic mitral heart valve.

The procedure was performed in Tor Vergata Hospital in Rome, Italy on a 72-year-old male suffering from severe mitral regurgitation who was ineligible for alternate treatments, the Irvine, Calif.-based company said.

“These untreatable patients are the reason I founded this company, and these are the patients we need to be able to help. It has taken a tremendous amount of work to get to this point, but I have never been more excited about the future of this technology and of TMVI. The ability to do a fully percutaneous mitral valve replacement with no incisions, no bypass support, and being able to extubate the patient while still in the cath lab is truly remarkable,” co-founder Dr. Arshad Quadri said in a press release.

“We have now performed three CardiAQ TMVI cases at Tor Vergata with excellent results, reducing the severe MR to trace and with no mitral or outflow tract gradients. We are convinced that these new procedures will in the future represent a substantial treatment improvement for our patients with mitral valve disease. Our heart team is excited to be a part of these groundbreaking clinical trials,” primary investigator Dr. Gian Paolo Ussia said in a prepared statement.

A CE Mark clinical trial for clearance in the European Union is slated for the end of summer, the company said.

“Additional transseptal feasibility cases will take place over the next few months, and we anticipate starting the European CE Mark clinical trial for our transseptal technology by the end of summer. Meanwhile, we are about to initiate the European CE Mark trial for our transapical system, which has already completed 9 feasibility cases. We are confident that the CardiAQ’s TMVI system will become a disruptive technology with an application as broad as the transcatheter aortic valve technology that was pioneered a decade ago,” COO Brent Ratz said in prepared remarks.

In April, CardiAQ said it won a nod from the FDA for an early feasibility trial of its 2nd-generation transcatheter mitral valve implant.

The 20-patient trial is slated to enroll 10 subjects to be treated transfemorally and another 10 treated via the transapical approach, CardiAQ Valve said. Boston’s Beth Israel Deaconess Medical Center will serve as the core lab for the study, the company said.

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Surgical Tagged With: CardiAQ Valve Technologies

More recent news

  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt
  • Penumbra completes enrollment in pulmonary embolism trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy